Voyager Therapeutics, Inc. announced the appointment of Peter Pfreundschuh as Chief Financial Officer (CFO). Peter Pfreundschuh has more than 25 years of finance, business development, commercial and public company leadership experience in the life sciences and medical device industries. Prior to joining Voyager, he served as CFO of Frequency Therapeutics, Inc., where Pfreundschuh provided executive leadership and guidance to help develop a path forward for the company's hearing program and communicate this to investors.

Prior to joining Frequency, Pfreundschuh served as CFO, Chief Compliance Officer and Corporate Secretary for UroGen Pharma Ltd., where he led the company in raising $162 million and helped transition the company from a development-stage entity to a commercial-stage company, successfully gaining FDA approval of and commercializing Jelmyto®. Prior to UroGen, Pfreundschuh was the CFO of Sucampo Pharmaceuticals Inc., a successful commercial-stage company, where he co-led the sale of Sucampo to Mallinckrodt. He also served in senior roles at Immunomedics Inc., CircuLite Inc., AstraZeneca, Johnson & Johnson and Ernst & Young, LLP.

Pfreundschuh is a certified public accountant and received his B.S. in accounting from Rutgers University and his MBA from Rider University. Pfreundschuh will report to Voyager CEO Al Sandrock, M.D., Ph.D., and will serve on Voyager's Senior Leadership Team. Pfreundschuh's appointment will become effective on September 19.